Clinical Trial Update: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and efficacy of doxycycline foam to prevent EGFR inhibitor–associated rash in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Doxycycline Foam (doxycycline)

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Rash Due to Epidermal Growth Factor Receptor Inhibitors | Phase 2 | Status: COMPLETED